Australian Osteoporosis Therapeutics Markets
Australian Osteoporosis Therapeutics Markets
RELEASE DATE
13-Dec-2005
13-Dec-2005
REGION
Asia Pacific
Asia Pacific
Research Code: 4B96-01-00-00-00
SKU: HC00140-AP-MR_02984
$3,950.00
In stock
SKU
HC00140-AP-MR_02984
Description
Osteoporosis is characterised by low bone mass and structural deterioration of bone tissue, causing increased susceptibility to fractures and chronic bone pain. The main therapies for the treatment of osteoporosis are hormone replacement therapy (HRT), bisphosphonates and selective oestrogen receptor modulators (SERMs). A key driver for the market is the lack of effective drugs that have a good safety and side effect profile. With a few drugs expected to enter the market over the forecast period, competition is expected to intensify. Stratification of the market should happen, so that companies should be able to serve niche markets. The current leader however, is expected to remain the dominant provider of osteoporosis medications.
Table of Contents
Executive Summary
- Market Overview
- Competitive Analysis
- Industry Issues and Challenges
- Market Opportunities and Forecasts
- Strategic Conclusions
Scope and Segmentation
- Scope and Segmentation
- Research Methodology
- Disease Introduction
Market Dynamics
- Demand Analysis
Factors Affecting Market Growth
- Market Drivers
- Market Challenges
- Revenue Forecast
Frost & Sullivan Awards for the Australian Osteoporosis Market
- 2005 Frost & Sullivan Awards
Bisphosphonates
Challenges for the SERMs Market
Challenges facing the Australian PTH market
Competitive Structure
Strategic Recommendations
Related Research
Popular Topics
Osteoporosis is characterised by low bone mass and structural deterioration of bone tissue, causing increased susceptibility to fractures and chronic bone pain. The main therapies for the treatment of osteoporosis are hormone replacement therapy (HRT), bisphosphonates and selective oestrogen receptor modulators (SERMs). A key driver for the market is the lack of effective drugs that have a good safety and side effect profile. With a few drugs expected to enter the market over the forecast period, competition is expected to intensify. Stratification of the market should happen, so that companies should be able to serve niche markets. The current leader however, is expected to remain the dominant provider of osteoporosis medications.
No Index | Yes |
---|---|
Podcast | No |
Industries | Healthcare |
WIP Number | 4B96-01-00-00-00 |
Is Prebook | No |